Urinary Tract Microbiota (UTM) Screening

Urinary Tract Microbiota (UTM) Screening

Urinary tract microbiota (UTM) and antibiotic resistance (ABR) testing at Radeas applies modern technology to improve diagnostic speed and accuracy. Using the latest molecular techniques, pathogens and potential resistance genes can be detected with greater sensitivity and specificity than traditional culture-based methods.

Radeas delivers accurate UTM and ABR screening when turnaround time is key for high-risk patient populations or patients with complex or recurring urinary tract infections. Culture based UTI diagnostic tests take longer, favor certain pathogens over others, and are limited in their antibiotic resistance determinations. The unbiased nature of the molecular methods at Radeas ensure that the presence of one pathogen will not mask the presence of the virulent pathogen, and that the identity of potential resistance genes can be determined, not just resistance to a particular antibiotic.

What Sets Radeas Apart in UTM Screening?

Accuracy Surpassing Industry Standard

Unlike the industry standard test, Radeas UTM/ABR testing can detect slow-growing and difficult-to-culture microorganisms that can be missed in urine cultures. Using Real-Time PCR, resistance can be detected simultaneously with detection of microorganisms. UTM/ABR testing at Radeas has greater accuracy, sensitivity, and scalability to provide fast results. Resistance can be identified by performing a secondary microbial resistance analysis, but is unlikely to be as robust as a molecular method.

Next-Day Results

Real-Time PCR testing from Radeas for UTM/ABR screening allows for analysis of pathogenic genetic components found within the urine sample. This enables Radeas to analyze samples quickly and produce next-business-day results. In comparison, culturebased UTI diagnostic testing often takes 3-5 days to produce results. Faster turnaround times empower early deployment of targeted treatment.

Comprehensive Next-Gen UTI Panel

Radeas UTM/ABR testing detects pathogens and resistance with highly sensitive molecular methods, testing for 26 common pathogens and 26 antibiotic resistances across a variety of pathogen classes and resistance subclasses. This produces accurate data, fast, allowing providers to target treatment for the individual patient.